Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632342 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1POLBHSD17B10 | |
| SCHEMBL13632346 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1POLBHSD17B10 | |
| SCHEMBL3083396 | 0.98 | MEN1 (0.44) | MEN1KMT2AALDH1A1POLBHSD17B10 | |
| SCHEMBL5429121 | 0.93 | MEN1 (0.41) | MEN1KMT2AALDH1A1POLBHSD17B10 | |
| SCHEMBL1543398 | 0.88 | HRH3 (0.40) | MEN1KMT2AALDH1A1POLBHSD17B10 | |
| SCHEMBL5016034 | 0.86 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10KCNH2 | |
| SCHEMBL1711612 | 0.82 | MEN1 (0.43) | MEN1KMT2AKDM4E | |
| SCHEMBL17850483 | 0.81 | MEN1 (0.47) | MEN1KMT2AALDH1A1KCNH2HRH3 | |
| SCHEMBL38657628 | 0.81 | MEN1 (0.47) | MEN1KMT2AALDH1A1KCNH2HRH3 | |
| SCHEMBL24302231 | 0.80 | PHGDH (0.56) | MEN1KMT2AALDH1A1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | claimed |
| CN-101255152-A | Preparation method and use of piperazine having cytotoxic activity | WENZHOU MEDICAL COLLEGE (CN) | 2008-09-03 | — | — | CN | claimed |
| EP-1170009-B1 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-2403878-B1 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 | SQUIBB & SONS LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-102333568-A | Pharmaceutical compounds | BIAL PORTELA & CA SA | 2012-01-25 | — | — | CN | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| CN-101255152-A | Preparation method and use of piperazine having cytotoxic activity | WENZHOU MEDICAL COLLEGE (CN) | 2008-09-03 | — | — | CN | disclosed |
| EP-1170009-B1 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-0880519-B1 | THIAZOLYLBENZOFURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6358992-B1 | Method of inhibiting neoplastic cells with indole derivatives | CELL PATHWAYS, INC. | 2002-03-19 | — | — | US | disclosed |
| EP-1170009-A2 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-09 | — | — | EP | disclosed |
| US-6069156-A | Indole derivatives as cGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-30 | — | — | US | disclosed |
| US-5994378-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| CN-1187812-A | Indole derivatives as CGMP-PDE inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-07-15 | — | — | CN | disclosed |
| EP-0820441-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032379-A1 | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | MEN1 2146/4885KMT2A 3625/4885ALDH1A1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.